Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Inclusion Criteria: * Diagnosis of advanced solid tumor cancer, lymphoma, or myeloma (no time restrictions or limitations) -OR- diagnosis of early stage solid tumor cancer, lymphoma, or myeloma \<= 12 months prior to study enrollment * Diagnosis of VTE \<= 30 days prior to study enrollment for which potential benefits of anticoagulation therapy to prevent recurrence of VTE are felt by the treating physician to exceed the potential harms * Any anticoagulation drug/strategy may be used to treat the index VTE; protocol treatment will begin \<= 30days after the index VTE diagnosis date * Treating physician intends to put participant on anticoagulation therapy for at least three months. * Age \>= 18 years * Platelet count is \>= 50,000/mm\^3 (\<= 7 days prior to enrollment) * CrCl (Creatinine Clearance) is \>= 15 ml/min (\<= 7 days prior to enrollment) Exclusion Criteria: * Diagnosis of acute leukemia * Has ever received or is scheduled to receive an Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) * Patients who have ever received an Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) ARE eligible. * Patients who are scheduled to receive an Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) are NOT eligible * Ongoing, clinically significant bleeding (CTCAE grade 3 or 4) * Ongoing therapy with a P-gp inhibitor (e.g., nelfinavir, indinavir, or saquinavir-protease inhibitors for HIV) as these drugs interact with the factor Xa inhibitors * Therapy with any azole antifungals (e.g., itraconazole, ketaconazole, voriconazole) at the time of enrollment